Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd Q1 FY25 Results & Presentation Highlights: Revenue ₹24.78 Cr, PAT ₹4.65 Cr
Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Shree Ganesh Remedies Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Q1FY25 EBITDA (excluding OI & EI): ₹8.12 crore, up 18% YoY - Q1FY25 EBITDA margin: 32.8%, improved by 703 basis points YoY - Q1FY25 Profit After Tax (PAT): ₹4.65 crore, up 3% YoY - Operating exp
From Shree Ganesh Remedies Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore.
- Total Income for Q1FY25: ₹25.32 crore, down 7% YoY from Q1FY24's ₹27.15 crore.
- The presentation does not provide explicit sales volume figures.
- Management Commentary highlights a slight YoY dip in revenue but notes healthy growth in EBITDA margins due to improved product mix and strategic raw material procurement.
- No specific quantitative revenue or volume outlook is stated.
- Strategic plans include completion of Block 7 (complex specialty chemicals) in ~18 months and commercial production ramp-up from Block 8 expected to contribute meaningfully by Q3FY25, implying potential future revenue growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Block 7 (Ankleshwar site)
- Focus: Complex, niche specialty chemicals via automated plant
- Status: Design phase
- Timeline: ~18 months for completion
- Block 8 (Ankleshwar site)
- Status: Completed in FY24; commercial production started Q1FY25
- Expected contribution: Meaningful by Q3FY25
- CAPEX: ₹15 crores
- Land acquisition (Ankleshwar)
- Additional 20,100 sq m acquired for expansion
- Total Ankleshwar land: 36,500 sq m
- CAPEX for acquisition: ₹26 crores
- Land acquisition (Dahej site)
- 40,554 sq m acquired in 2022
- Capital outlay: ₹11 crores
- Site development started (fencing, ground leveling)
- Expansion: Phased manner, projects under evaluation
- Future Capacity
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key investor presentation takeaways from NG
- Themis Medicare Ltd (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q1 FY25 investor presentation — and how it ranks against sector
- Fermenta Biotech Ltd (Q1 FY25)
The Annual Standalone Financial Performance (Page 26) reports full-year FY24 operational revenue of INR 3,071 million, down 6.6% YoY from INR 3,289 million in…
- Fermenta Biotech Ltd (Q1 FY25)
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Key investor presentation takeaways from Fermenta Biotech L
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q1 FY25 results?
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Q1FY25 EBITDA (excluding OI & EI): ₹8.12 crore, up 18% YoY - Q1FY25 EBITDA margin: 32.8%, improved by 703 basis points YoY - Q1FY25 Profit After Tax (PAT): ₹4.65 crore, up 3% YoY - Operating exp
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Block 7 (Ankleshwar site) - Focus: Complex, niche specialty chemicals via automated plant - Status: Design phase - Timeline: ~18 months for completion - Block 8 (Ankleshwar site) - Stat
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.